Table 1.
Baseline characteristics, ICU parameters and outcome in patients admitted to ICU with COVID-19 who received CRRT.
| Baseline characteristics of CRRT cohort | ||
| Age(years) Median, (IQR) | 60 | (54–65) |
| Women N, % | 8 | 9.7 |
| Length of ICU stay (days) | 23 | (15–26) |
| SAPS III N = 75 Median Score, (IQR) | 61 | (53–71) |
| BMI (kg/m2) N = 72 Median, (IQR) | 29 | (25–32) |
| Over 30 kg/m2N, (% of N) | 28 | 38.9 |
| Over 40 kg/m2N, (% of N) | 4 | 5.5 |
| Comorbidity | N | % |
| Hypertension | 31 | 37.8 |
| Diabetes type I or II | 19 | 23.2 |
| Chronic renal failure (grade IV or V) | 5 | 6.1 |
| Any malignancy | 2 | 2.4 |
| Chronic pulmonary disease | 7 | 8.5 |
| Rheumatic disease | 2 | 2.4 |
| Cerebrovascular disease | 4 | 4.8 |
| Myocardial infarction | 1 | 1.2 |
| Peripheral vascular disease | 1 | 1.2 |
| Congestive cardiac failure | 4 | 4.0 |
| Lab values | Median | IQR |
| Baseline Creatinine(μmol/l)a | 83 | 72–94 |
| Admission Creatinine (μmol/l) | 83 | (72–110) |
| Highest ICU Creatinine (μmol/l) | 437 | (353–542) |
| Highest ICU Urea (mmol/l) | 36 | (25–42) |
| Highest ICU Cystatin C (mg/l) | 5.3 | (4.5–5.9) |
| Highest ICU myoglobin (ug/L) N = 80 | 4130 | (1488–6842) |
| Weight at ICU admission (N = 75) | 89 | (75–100) |
| Median discharge weight (N = 60) | 81 | (70–92) |
| Weight loss during ICU stay (kg) (N = 60) | −6.0 | (−11.8–1.6) |
| Percentage weight loss during ICU stay (%) (N = 60) | −7.2 | (−12.8–2.1) |
| Intervention | ||
| Mechanical ventilation N, (%) | 82 | 100 |
| ECMO N, (%) | 7 | 8.5 |
| CRRT only N, (%) | 62 | 76 |
| CRRT and IHD N, (%) on ICU | 32 | 40 |
| Number of days of CRRT Median (IQR) | 12 | [[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21]] |
| Number of days of IHD Median (IQR) | 3 | [[2], [3], [4], [5], [6]] |
| Mortality | N | % |
| ICU mortality | 32 | 39.0% |
| 60-day mortality | 37 | 45.1 |
| 90-day mortality | 37 | 45.1 |
| Hospital mortality | 37 | 45.1 |
| Follow-up data (N = 42) | Median | IQR |
| Creatinine umol/l, N = 42 | 97 | (73–116) |
| Last registered Cystatin C, (mg/l) N = 26 | 1.52 | (1.4–1.9) |
| eGFR creatinine-based (ml/min/1.73m2) N = 42 | 66 | (56–78) |
| eGFR cystatin C based (ml/min/1.73m2) N = 26 | 47 | (37–53) |
| Weight at follow-up (kg) N = 39 | 85 | (77–98) |
| Follow up weight as percent of baseline (%) N = 39 | −3 | (−17 − +17) |
| AKD n (% of survivors with data (N = 42)) | 11 | 26.2 |
IQR Interquartile range.
SAPS Simplified physiology score III.
BMI Body mass index.
ECMO Extra corporeal membrane oxygenation.
CRRT Continuous renal replacement therapy.
IHD Intermittent Haemodialysis.
AKD Acute Kidney Disease.
eGFR estimated glomerular filtration rate.
a
Estimated in 12 patients.